The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Market Value Is Anticipated For The Esketamine Market Over The Period 2026–2030?
The esketamine market has experienced swift expansion in recent years. It is forecast to rise from $1.51 billion in 2025 to $1.67 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.8%. The historical increase in market size is due to unaddressed requirements in major depressive disorder, the constraints of conventional antidepressants, regulatory clearances for nasal esketamine, a growing understanding of mental health, and the establishment of specialty psychiatric clinics.
The esketamine market is projected to experience substantial expansion over the upcoming years. By 2030, its valuation is anticipated to reach $2.5 billion, demonstrating a compound annual growth rate (CAGR) of 10.6%. This projected increase during the forecast period stems from factors such as the rising incidence of treatment-resistant depression, a heightened need for rapidly effective treatments, the broader availability of supervised outpatient administration, improvements in mental health infrastructure, and ongoing investment in clinical research. Key developments expected throughout this period involve the greater acceptance for treatment-resistant depression, the wider use of nasal spray delivery methods, increased application in acute psychiatric care environments, enhanced oversight and regulated distribution, and intensified investigation into swift-acting antidepressants.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=23393&type=smp
Which Economic Or Industry Drivers Are Impacting The Esketamine Market?
The increasing prevalence of treatment-resistant depression (TRD) is anticipated to propel the growth of the esketamine market in the coming years. Treatment-resistant depression (TRD) refers to depression that does not show improvement after attempting at least two different antidepressant medications at appropriate doses for a sufficient duration. The rise in treatment-resistant depression (TRD) is due to the limited effectiveness of conventional antidepressants, leading to prolonged and recurring depressive episodes. Esketamine aids treatment-resistant depression (TRD) by offering a fast-acting mechanism that targets NMDA receptors, providing relief for patients who do not respond to traditional antidepressants. For instance, in September 2023, the National Institute of Mental Health (NIMH), a US-based federal agency, reported that, in 2023, about 30% of individuals with major depressive disorder in the U.S. are resistant to standard treatments. Therefore, the rising incidence of treatment-resistant depression is driving the growth of the esketamine market.
How Is The Esketamine Market Divided Into Its Major Segments?
The esketamine market covered in this report is segmented –
1) By Formulation Type: Nasal Spray, Injectable Form
2) By Indication: Treatment-Resistant Depression (TRD), Major Depressive Disorder with Suicidal Ideation or Behavior
3) By Patient Type: Adult Patients
4) By Treatment Setting: Hospital-Based Administration, Certified Specialty Clinics
5) By Distribution Channel: Hospital Pharmacies, Specialty Pharmacies
Subsegments:
1) By Nasal Spray: Single-Agent Esketamine Nasal Spray, Esketamine + Oral Antidepressant Combination Therapy
2) By Injectable Form: Intravenous (IV) Esketamine, Intramuscular (IM) Esketamine
How Are Trends Transforming The Esketamine Market Landscape?
Leading companies in the esketamine market are concentrating on developing advanced therapeutic solutions, such as monotherapy, to boost the relief of depressive symptoms beyond what a placebo can offer. Monotherapy refers to the application of a single drug or treatment for managing a disease or medical condition, rather than integrating multiple therapies. For example, in January 2025, Johnson & Johnson, a US-based pharmaceutical entity, disclosed that the U.S. Food and Drug Administration (FDA) had granted approval for SPRAVATO (esketamine) as the initial and only monotherapy for adults experiencing treatment-resistant depression (TRD). Endorsed by clinical trials, this approval demonstrated SPRAVATO’s capacity to swiftly ease depressive symptoms, with considerable improvements observed within 24 hours. This innovation presents a crucial choice for approximately 30% of individuals who do not respond to conventional antidepressants, thereby eliminating the necessity for concurrent oral medications. While SPRAVATO exhibits a favorable safety profile, it is administered within a Risk Evaluation and Mitigation Strategy (REMS) to manage potential adverse reactions. This landmark signifies a substantial progression in TRD treatment, providing renewed optimism for better patient outcomes.
Who Are The Prominent Organizations Shaping The Esketamine Market?
Major companies operating in the esketamine market are Johnson & Johnson, Janssen Pharmaceuticals, Sage Therapeutics Inc., VistaGen Therapeutics Inc., Cerecor Inc., Celon Pharma S.A., Hikma Pharmaceuticals plc, Seqens Group, Arevipharma GmbH, Nortec Química S.A., Supriya Lifescience Ltd., Maithri Drugs Pvt. Ltd., SynZeal Research Pvt. Ltd., XWPharma Ltd., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Lupin Limited, Aurobindo Pharma Ltd., H. Lundbeck A/S, Otsuka Pharmaceutical Co. Ltd.
Read the full esketamine market report here:
https://www.thebusinessresearchcompany.com/report/esketamine-global-market-report
What Are The Top-Performing Regions Within The Esketamine Market?
North America was the largest region in the esketamine market in 2025. The regions covered in the esketamine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Esketamine Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=23393&type=smp
Browse Through More Reports Similar to the Global Esketamine Market 2026, By The Business Research Company
Epinephrine Market Report 2026
https://www.thebusinessresearchcompany.com/report/epinephrine-global-market-report
Anti Infective Drugs Market 2026
https://www.thebusinessresearchcompany.com/report/anti-infective-drugs-market
Anticholinergic Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/anticholinergic-drugs-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model